Lee Pharmaceuticals (LPHM) 0.0060 $LPHM The Inc
Post# of 273308
Posted On: 07/11/2015 7:01:05 PM
Lee Pharmaceuticals (LPHM) 0.0060 $LPHM
The Incidence of Diabetes inside China keeps Growing and the Market Size of Diabetes Drugs Has Expanded Each Year, Exceeding CNY 20 Billion in 2014
M2 - Thu Jun 11, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62kjcv/investigation) has announced the addition of the "Investigation Report on China's Insulin Glargine Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while in America it will reach 29.7 million. The fast growth rate of diabetes in China and other developing countries has put a heavy burden on their social and economic development. In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition. According to the author's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014- 2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in February 2015, the global market structure is estimated to change in the next few years. On September 9th 2014, Eli Lilly and Company and Boehringer- ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in the Chinese market, some local enterprises are also hastening the development of Lantus's generic drug. Companies Mentioned: - Gan & Lee Pharmaceuticals - Aventis Behring GmbH - Tonghua Dongbao Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/62...estigation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 88.29 (+0.81)
The Incidence of Diabetes inside China keeps Growing and the Market Size of Diabetes Drugs Has Expanded Each Year, Exceeding CNY 20 Billion in 2014
M2 - Thu Jun 11, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62kjcv/investigation) has announced the addition of the "Investigation Report on China's Insulin Glargine Market, 2010-2019" report to their offering. According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while in America it will reach 29.7 million. The fast growth rate of diabetes in China and other developing countries has put a heavy burden on their social and economic development. In China, the third generation of insulin is still in promotion period. Since its price is relatively high, it is mainly used in big cities. The second generation and the third generation of insulin will take the shape of stagger competition. According to the author's survey on some sample hospitals in China, the CAGR of insulin glargine in sample hospitals in China has exceeded 60% during the period of 2014- 2015. Currently, the Chinese market is dominated mainly by Aventis Behring Gmbh (the trade name of insulin glargine is Lantus and the sales in 2014 exceeded USD 7 billion) and the generic drugs (the trade name of insulin glargine is Basalin) made by Gan & Lee Pharmaceutical. As the patent of Lantus expired in February 2015, the global market structure is estimated to change in the next few years. On September 9th 2014, Eli Lilly and Company and Boehringer- ingelheim issued a joint statement that the insulin biosimilar - insulin glargine owned by them has been approved to come into market by the EU. On the other hand, in the Chinese market, some local enterprises are also hastening the development of Lantus's generic drug. Companies Mentioned: - Gan & Lee Pharmaceuticals - Aventis Behring GmbH - Tonghua Dongbao Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/62...estigation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
LLY: 88.29 (+0.81)
(0)
(0)